文献速递银屑病与炎症性皮肤病

法国国家医保数据库银屑病治疗患者的真实世界流行病学研究

Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-06-09

BACKGROUND: Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world. Data on the prevalence of psoriasis in adults differ depending on the study.…

要点

  • 法国银屑病治疗患者患病率约1.3%,可能因仅纳入治疗患者而低估。
  • 13%的银屑病患者曾接受至少一种系统治疗。
  • 系统治疗患者常见共病包括高血压、血脂异常、糖尿病和慢阻肺。

核心结论

  • 法国银屑病治疗患者患病率估计为1.3%,低于其他研究,可能因仅识别治疗患者而低估。
  • 需系统治疗患者的共病谱与其他数据来源研究相似,提示该数据库能捕捉中重度银屑病。

研究设计与样本

  • 法国全国性队列研究,基于国家医保数据库链接国家医院出院数据库(SNDS-PMSI)。

主要发现

  • 银屑病相关最常见共病为高血压、血脂异常、糖尿病和慢性阻塞性肺疾病。

临床怎么用

  • 医保数据库可用于估计银屑病治疗人群的患病率和系统治疗使用情况。
  • 系统治疗患者应关注高血压、血脂异常、糖尿病和慢阻肺等共病筛查。

局限性

  • 仅识别接受治疗的患者,患病率可能被低估。
  • 基于行政数据库,可能受编码准确性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Psoriasis is one of the most frequent chronic inflammatory dermatoses in the world. Data on the prevalence of psoriasis in adults differ depending on the study. OBJECTIVE: To estimate the prevalence of patients with treatment for psoriasis in France and to identify and characterize patients receiving systemic treatments. METHODS: This was a French, nationwide cohort study based on health administrative data from the French national health insurance scheme linked to the national hospital discharge database (SNDS-PMSI). All adults with psoriasis registered in the SNDS between 1 January 2008 and 31 December 2016 were eligible for inclusion. All patients with a new prescription for a systemic treatment for psoriasis were included. RESULTS: A total of 874 549 patients were identified as having psoriasis (mean ± SD age 53.8 ± 17 years; 52.4% males); 112 969 (13%) had filled at least one prescription for a systemic medication used to treat psoriasis. The prevalence of patients with treatment for psoriasis was estimated at 1.3%. Overall, 73 168 and 16 545 were new users of conventional systemic treatments and biologics, respectively. The most frequent comorbidities associated with psoriasis were hypertension, dyslipidaemia, diabetes and chronic obstructive pulmonary disease. CONCLUSION: The prevalence of psoriasis we found was lower than in other studies. It was probably underestimated because we identified only patients with treatment for psoriasis. Our results concerning comorbidities associated with psoriasis patients requiring systemic treatment were similar to those from other published studies using other data sources, highlighting our ability to catch moderate-to-severe psoriasis. This study highlights the usefulness and reliability of the use of insurance databases in studies, because they allow for a better application to the general population.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Grodner C, Sbidian E, Weill A, et al. Epidemiologic study in a real-world analysis of patients with treatment for psoriasis in the French national health insurance database. J Eur Acad Dermatol Venereol. 2020. PMID: 32364321. doi:10.1111/jdv.16566

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。